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A high proportion of patients with acute myeloid leukemia who achieve minimal residual disease negative 
status ultimately relapse because a fraction of pathological clones remains undetected by standard methods. 
We designed and validated a high-throughput sequencing method for minimal residual disease assessment 
of cell clonotypes with mutations of NPM1, IDH1/2 and/or FLT3-SNV. For clinical validation, 106 follow-
up samples from 63 patients in complete remission were studied by sequencing, evaluating the level of 
mutations detected at diagnosis. The predictive value of minimal residual disease status by sequencing, 
multiparameter flow cytometry, or quantitative PCR was determined by survival analysis. The method 
achieved a sensitivity of 10-4 for single nucleotide variant and 10-5 for insertions/deletions and could be used 
in acute myeloid leukemia patients who carry any mutation (86% in our diagnosis data set). Sequencing–
determined minimal residual disease positive status was associated with lower disease-free survival (hazard 
ratio 3.4, p=0.005) and lower overall survival (hazard ratio 4.2, p<0.001). Multivariate analysis showed that 
minimal residual disease positive status by sequencing was an independent factor associated with risk of 
death (hazard ratio 4.54, p =0.005) and the only independent factor conferring risk of relapse (hazard ratio 
3.76, p =0.012). This sequencing-based method simplifies and standardizes minimal residual disease 
evaluation, with high applicability in acute myeloid leukemia. It also improves upon flow cytometry and 
quantitative PCR to predict acute myeloid leukemia outcome and could be incorporated in clinical settings 




Cytogenetic and molecular alterations at diagnosis and response to treatment are the most useful criteria to 
predict relative risk of relapse in acute myeloid leukemia (AML), and to guide the choice between 
chemotherapy and hematopoietic stem cell transplantation (HSCT) in first complete remission (CR).(1) The 
definition of CR for AML includes criteria for the identification of patients with poor prognosis using 
cytomorphological methods.(2) But, these studies do not have a good predictive value because most of the 
CR cases relapse within 3 years of diagnosis.(3)  
 
Assessment of minimal residual disease (MRD) is critical in monitoring patients in morphological 
remission, to inform decisions about further therapy.(1) Indeed, several studies have reported MRD status as 
a stronger predictor of relapse, because patients who are MRD negative have a better prognosis than those 
who are MRD positive.(4, 5) In support of this, recent non-randomized studies from prospective multicenter 




AML is, nevertheless, a biologically complex and heterogeneous disease, which makes MRD testing 
challenging when compared with other hematological neoplasms such as acute lymphoblastic leukemia or 
multiple myeloma. The detection of very low levels of MRD by conventional methods such as quantitative 
(q)-PCR or multiparameter flow cytometry (MFC) provides powerful independent prognostic information. 
Unfortunately, as described for cytomorphological CR, many patients who achieve MRD negative status 
relapse as a result of the progression of undetected leukemic cells. The most common method for MRD 
detection is MFC, with intermediate applicability (70–80%) and limited sensitivity.(9, 10) However, there is 
no consensus on multi-antibody panels with regards to inter-laboratory performance, and the technique 
requires a high level of expertise. The other principal MRD monitoring method, qPCR, has good sensitivity 
(10-4–10-6), but its applicability is limited in up to 40% of patients who present molecular alterations 
(RUNX1-RUNX1T1, CBFβ-MYH11 or NPM1) at diagnosis.(11) 
 
For the above reasons, new methods with higher sensitivity, specificity, applicability and performance are 
needed for MRD assessment in AML. Against this background, next-generation sequencing (NGS) and 
digital PCR (dPCR) have recently emerged as potentially promising platforms to assess MRD.(12) Here, we 
optimized and clinically validated a new deep targeted NGS-based method, supported with dPCR technical 
validation, for MRD detection and quantification (both small insertion/deletions [InDels] and single 
nucleotide variants [SNVs]) in AML patients, in an attempt to improve and/or complement the current 
MRD evaluation techniques, and to establish its potential as a predictor of patient outcome. 
 
Methods 
More detailed information can be found in the Online Supplementary data (1–6). 
 
Patients and samples 
One hundred and ninety patients with de novo or secondary non–M3 AML were included in mutational 
profile screening at diagnosis. We performed a new selection for retrospective MRD assessment using the 
following criteria: presence of the NPM1 type A mutation, or SNVs in FLT3, IDH1 and/or IDH2 at 
diagnosis, and availability of at least one follow-up genomic (g)-DNA sample.  
 
The MRD approach included 51 (48%) follow-up samples taken at post-induction, and 55 (52%) at post-
consolidation time, corresponding to 63 patients diagnosed between 2006 and 2016 (for selection criteria 
see Online Supplementary 6 and Supplementary Table S1). Patients were treated according to PETHEMA 
(Programa Español de Tratamientos en Hematología) or CETLAM (Grupo cooperativo de Estudio y 
Tratamiento de Leucemias Agudas y Mielodisplasias) protocols. The study was conducted according to the 
 
Spanish law 14/2007 of biomedical research, and was approved by the Research Ethics Board of each 
participating institution. All patients provided informed consent. The main clinical characteristics of patients 
are summarized in Table 1. All patients achieved CR by cytomorphological criteria after induction therapy 
(<5% of bone marrow blasts).  
 
To construct calibration curves, commercial (Horizon Discovery, UK) reference standard gDNA was used 
for somatic SNVs in IDH1 (R132C) and IDH2 (R172K). As a further source of gDNA, we used the OCI-
AML3 cell line (ACC 582, DSMZ, Germany) with the NPM1 type A mutation (c.863_864insCCTG) to 
examine InDels. As OCI-AML3 cells also present a SNV in DNMT3A (R882C), this was included only for 
technical optimization. 
 
Deep targeted sequencing workflow 
The sequencing workflow included one first study at diagnosis and a second study at follow-up. Mutational 
profile screening at diagnosis was done with a custom NGS myeloid panel of 32 genes frequently mutated 
in myeloid diseases,(13) (Online Supplementary Table S2) and NPM1 analysis was carried out with qPCR.(14) 
 
The specific mutations detected at diagnosis were studied at follow-up. A variety of experimental steps were 
first tested to define optimal conditions (Online Supplementary 1). We established an optimal protocol 
(Figure 1) that included DNA amplification, library preparation and sequencing as experimental steps 
(Online Supplementary 2).   
 
Libraries were sequenced on the Ion Proton System platform (Life Technologies, Thermo Fisher Scientific 
Inc.) with an estimated depth ≥ 1,000,000 of reads, generating .fastq files. These files were analyzed using a 
custom bioinformatic pipeline; which leads from the .fastq file and a .csv file that contains information 
about name identifier, run and barcode identifier, chromosomal position and the variant detected in the 
diagnosis to be evaluated in the follow-up sample. Through Ensembl Perl API,(15) the aligned mutated 
sequence and the aligned wild type (wt) sequence are presented in FASTA format (sequences of 40 bp). 
Finally, we obtained a .csv file containing the name identifier, run and barcode identifier, chromosomal 
position, the variant, the specific target sequence in FASTA format (mutated forward, mutated reverse, wt 




A high percentage of AML patients could benefit from deep sequencing MRD approach 
 
 
In total, 211 (80%) SNVs and 46 (20%) InDels were detected in the 190 patients analyzed at diagnosis 
using the NGS custom panel. We detected one variant (SNV or InDel) in 48 (25%) cases, 2 or more variants 
in 116 (61%) cases and no variants in 26 (14%) cases. In addition, we detected the NPM1 type A mutation 
in 53 (28%) patients by qPCR. Genes (TET2, ASXL1, or DNMT3A) with evidence of clonal hematopoiesis 
of indeterminate potential (CHIP) association were excluded from the analysis.(11) Consequently, 82% of 
patients in our cohort could benefit from this approach.  
 
Based on those genes reported as potential markers to monitor MRD,(16) and also the availability of follow-
up samples, we focused on IDH1/2 and FLT3-SNV. We identified at diagnosis IDH1 mutations in 13 
patients (7%), IDH2 mutations in 27 patients (14%) and FLT3-SNV mutations (18%) in 34 patients. 
 
Deep sequencing MRD has a sensitivity of 10-4 for SNVs and 10-5  for InDels 
 
To establish the limit of quantification (LOQ) of the method, we used 10-fold serial dilutions of mixed 
mutated and control DNA. To study prototype InDels, we used gDNA from OCI-AML3 cells (NPM1 type 
A) and to study prototype SNVs, we used both gDNA from OCI-AML3 cells (DNMT3A) and commercial 
reference gDNA (IDH1/IDH2). As a control, we used a pool of gDNA from ten individuals without somatic 
mutations in these chromosomal regions. In all cases, initial allele frequency was 50% and a total of six 
dilutions were carried out to construct a calibration curve, covering a theoretical dynamic range from 10-1 to 
10-7.  
As shown in Figure 2A, B, MRD NGS testing of NPM1 (InDel) could quantify one mutated cell in the order 
of 10-5, and in the case of SNVs (IDH1, IDH2 and DNMT3A) the LOQ was 10-4, which was reproducible for 
all SNVs tested. 
 
NGS is more sensitive than dPCR for MRD testing 
 
We compared the sensitivity of sequencing with that of dPCR using the same LOQ dilution protocol. Clone 
frequency expressed as target concentration (mutated copies/μL in wt copies/μL) gradually decreased with 
each dilution, reaching an LOQ of 10-3 for NPM1, IDH1 and IDH2 (Figure 2C–D). While both methods 
showed similar detection limits and good linearity, the LOQ for the sequencing method was one order of 
magnitude higher than that for dPCR (IDH1 and IDH2), and two orders of magnitude higher for InDels 
(NMP1). 
 
MRD status tested by sequencing has prognosis impact in AML   
 
 
Median of depth coverage was 401,300 aligned reads (interquartile range 195,100–825,700) for the 88 
NPM1 and 18 SNV (9 IDH1, 7 IDH2, and 2 FLT3) follow-up samples evaluated. We detected no mutated 
sequence in 13 (12%) samples, 1–5 mutated sequences in 19 (18%) samples, and more than 10 in 74 (70%) 
samples. The ratio of mutated sequences to wt sequences defined MRD levels. Considering MRD levels 
from the 106 samples evaluated we established the optimal cutoff to classify MRD status (positive vs 
negative) by ROC curves (Online Supplementary Figure S1) at each check-point of MRD evaluation (post-
induction [n=51], post-consolidation [n=55],  or both together [n=106]).  
 
Survival analysis revealed that positive MRD status (MRD levels > 0.1%) at post induction (n=35) was 
associated with a significantly lower rate of overall survival (OS) (33% vs. 78%; hazard ratio [HR]: 3.5; 
95% confidence interval [CI]: 1.1–10.7; p=0.019), but a non-significant lower rate of disease-free survival 
(DFS) (58% vs. 78%; HR: 2.18; 95%CI: 0.63–7.5; p=0.208) (Figure 3A, B). At post-consolidation (n=28), 
MRD positive status (MRD levels > 0.025%) was associated both with significantly shorter OS (33% vs. 
81%; HR: 6.0; 95% CI: 1.3–28.7; p<0.001), and significantly shorter DFS (17% vs. 94%; HR: 19.6; 95% 
CI:2.5–155.6; p<0.001) (Figure 3C, D). Also, survival analysis was performed combining post-induction 
and post-consolidation (n=63), in order to compare survival analysis with MFC and qPCR data sets. We 
observed that positive MRD status (MRD levels > 0.035%) was associated with a higher risk of relapse 
(48% vs. 81%; HR: 3.4; 95% CI: 1.4–8.5; p=0.005) and death (37% vs. 81%; HR: 4.2; 95% CI: 1.6–10.7; 
p<0.001) (Figure 3E, F). In order to test the power of NPM1 and SNVs as independent predictive markers, 
we performed the analysis separately.  Evaluating NPM1 as an MRD marker (n=54), we found that MRD 
positive status was associated both with significantly shorter OS (43% vs. 78%; HR: 3.3; 95%CI: 1.2–8.8; 
p=0.011), and shorter DFS (57% vs. 85%; HR: 2.9; 95%CI: 0.9–7.6; p=0.052), and the similar results are 
found when we evaluated IDH1, IDH2 or FLT3-SNV as MRD markers (n=11). Accordingly, MRD positive 
status was associated both with significantly shorter OS (17% vs. 100%; HR: NA; p=0.041), and shorter 
DFS (17% vs. 75%; HR:6.3; 95%CI:0.7–54; p=0.058). 
 
In univariate Cox analysis (Table 2A), the risk of death was significantly higher in patients with increased 
age (HR: 1.04; p=0.013), those with FLT3-ITD (HR: 3.45; p=0.007), and those with MRD positive status 
tested by NGS (HR: 4.22; p=0.002). Risk of relapse was significantly higher only in those patients with 
MRD positive status tested by NGS (HR: 3.4; p=0.008). In multivariate analysis (Table 2B), the risk of 
death was significantly higher in patients with increased age (HR: 1.05; p=0.004), those with mutated FLT3-
ITD (HR: 8.87; p=0.001), and those with MRD positive status tested by NGS (HR: 4.54; p=0.005).  The 
risk of relapse was higher only in patients MRD positive patients tested by NGS (HR: 3.76; p=0.012). 
 
MRD tested by sequencing improves prediction of OS and DFS over MFC and qPCR  
 
 
A positive correlation was found when comparing MRD assessment by NGS vs MFC (r=0.47, p=0.005, 
n=75), and NGS vs qPCR (r=0.62, p<0.001, n=80) (Online Supplementary Figure S2). There were 
differences between positive MRD and negative MRD groups of patients tested by MFC, but they were not 
significant for OS (p=0.193) or DFS (p=0.117) (n=46, Figure 4A). Similarly, differences were observed 
between positive MRD and negative MRD groups by qPCR of NPM1, although significance was not 




We have optimized and validated a high sensitivity NGS method to detect and quantify NPM1, IDH1, IDH2 
and FLT3-SNV mutated sequences at very low allele frequency in follow-up gDNA samples. NGS has 
demonstrated prognostic value for pre-treatment status in patients with AML,(17) and may also be a useful 
tool to detect MRD.(18, 19) We first studied the mutational profile of patients with AML using a  custom NGS 
panel to ensure a high applicability (82% of patients). This approach is also a useful screening method to 
detect all potential MRD markers and to choose those most relevant. The combination of several markers is 
possible and recommended to overcome limitations of MRD assessment that are due to sub-clonal 
heterogeneity of AML and to CHIP.(11) Accordingly, our method has the capacity to evaluate multiple 
markers simultaneously and, considering that 61% of patients in our cohort had two or more genetic 
alterations this approach is sufficiently robust to monitor MRD in patients even if they present clonal 
evolution. 
 
Reported variants associated with CHIP are frequently located in DNMT3A, TET2 or ASXL1 genes, and are 
detected at the preleukemic phase and at complete AML remission.(20-23) Indeed, any gene could carry both 
CHIP and non-CHIP variants, and these should be evaluated for each patient. Moreover, studies have shown 
that genes related to CHIP (IDH1/2) are useful for predicting prognosis because in these cases the genetic 
alterations have been acquired in the leukemic clone and not before.(24) 
 
The sensitivity achieved with this method equates to one mutated cell per 100,000 cells (LOQ 10-5) for 
NPM1 and one mutated cell per 10,000 cells (LOQ 10-4) for IDH1, IDH2 and FLT3-SNV. This difference in 
sensitivity is related to the fact that the NPM1 type A (insCCTG) mutation is rarely generated erroneously 
by NGS, and the quantification is precise.  
 
Our method, as with any NGS method, has an intrinsic error rate that limits its sensitivity for most SNVs to 
1–2% of all reads. This limitation can nevertheless be overcome by virtue of the scalable nature of NGS.(16) 
 
Thus, we boosted NGS sensitivity by increasing the amount of DNA by PCR prior to sequencing, which 
increased the depth of coverage to one million reads. By also optimizing the bioinformatic analysis, we 
focused the search for the precise variant in order to eliminate random sequencing errors, enhancing the 
specificity of the technique and reducing the computational time. To the best of knowledge, our NGS 
method presents possibly the highest sensitivity reported for NGS in AML.(18, 19, 24-27) 
 
dPCR is a relatively novel technique for precise and absolute quantification of nucleic acids, which is based 
on limiting partitions of the PCR volume and Poisson statistics.(28) It is also an extremely sensitive 
technique, with a high specificity due to the detection of mutant alleles.(29) However, when we compared 
the same standard dilutions in NGS and dPCR, NGS afforded a 2-log increment in LOQ for InDels (NPM1) 
and a 1-log increment for SNVs (IDH1/2), with the sensitivity of dPCR for InDels similar to that reported 
in a previously published study (10-2).(30) Compared with NGS, dPCR is a faster measurement technique 
but, as it is focused, it requires allele-specific primers that can complicate the experimental procedure, and a 
high number of parallel experiments are needed to raise the sensitivity, increasing the cost of the assay. 
Additionally, although it is possible to multiplex dPCR, unfortunately only a few targets can be monitored 
simultaneously within each sample.(29) Another advantage of NGS technology is that it does not require 
calibration curves in each assay, and the results are reported in absolute values, facilitating its 
standardization.   
 
The NGS method described in this report showed comparable sensitivities (10-4 for SNVs and 10-5 for 
InDels) to MFC methods in those cases with immunophenotyphically aberrant populations.(10, 31) Although 
our method showed a similar sensitivity to that of qPCR, it does not require oligonucleotides that hybridize 
specifically to a particular sequence, so all nucleotides in the amplified region can be studied. Consequently, 
the NGS test is capable of detecting all NPM1 subtype mutations in the same assay.  
 
We found positive correlations when MRD levels were evaluated by NGS vs MFC and vs qPCR, but not 
with the expected results. In the case of MFC, this could be explained, in part, because NPM1 mutations are 
usually associated with monocytic subtype-AML, which frequently presents more difficulties for identifying 
MRD by MFC. Indeed, Salipante et al(27) described that the level of success of MFC depends greatly on the 
immunophenotype of the abnormal blasts and how to discriminate them from background regenerative 
blasts. Moreover, due to the lack of standardization, MFC shows substantial variability across laboratories, 
including that of sample processing, instrument configuration, number of events, and training of 
pathologists.(32) The lack of a strong correlation between NGS and qPCR could be explained by the nature 
of the sample (sequencing uses gDNA whereas qPCR uses cDNA). Although RNA overexpression allows a 
higher sensitivity of detection, RNA levels do not correlate with the number of tumoral cells, in contrast to 
 
mutated DNA. Accordingly, mutated DNA is more representative of the tumoral burden than is 
overexpression of mutated RNA.(33) It should be noted that the prediction of survival and progression of 
AML using MRD NGS was improved over the other methodologies employed, at least in the cohorts 
evaluated.  
 
Finally, survival analysis showed that MRD positive status tested by NGS was associated with a higher risk 
of relapse and death and that MRD negative status at post-consolidation was associated with a longer OS 
and DFS; as according to recently published studies.(23) Supporting these findings, previous studies reported 
that an MRD check-point at post-consolidation could be the best moment for analysis because a better 
prediction is observed.(8, 34-37) Cox regression multivariate analyses confirmed that MRD positive status by 
sequencing was the only factor with significant risk prediction of relapse (p=0.012).   
  
In conclusion, we have optimized a new targeted sequencing method with high sensitivity for MRD 
evaluation with applicability for a high percentage of AML patients, improving the capacity to predict the 
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BM indicates bone marrow; PB, peripheral blood; AML, acute myeloid leukemia; ITD, internal tandem 
duplications; TKD, tyrosine kinase domain; allo-HSCT, allogeneic HSCT and auto-HSCT, autologous 
HSCT. *3+7 regimen of chemotherapy: one or two induction cycles of cytarabine and idarubicin during 
PATIENTS (n = 63) 








21 (33%)  
42 (67%) 
Age at diagnosis  
Median 54 (IQR, 41.5–66.0) 
Blasts at diagnosis   
Median count 69 (IQR, 51.0–81.0) 
Leukocytes at diagnosis  
Median count (×10
9/L) 15.7 (IQR,12.2–20.24) 
AML secondary   
No  
Yes 
59 (94%)  
  4 (6%)  





36 (57%)  
  2 (3%) 
FLT3-ITD  
FLT3 negative  
FLT3 positive 
FLT3-TKD 
FLT3 negative  
FLT3 positive 
NPM1 





 60 (95%) 
   3 (5%) 
 
   6 (10%) 
 57 (90%) 
HSCT   
No  42 (67%)  
allo-HSCT  
auto-HSCT 










40 (63%)  
23 (37%) 
Treatment*   
3+7 regimen  
Flugaza 
50 (80%)  
  8 (13%) 
Mylotarg   2 (3%) 
Panobidara   3 (4%) 
 
seven and three days, respectively; and two or three consolidation cycles at high doses of cytarabine, twice a 
day for three alternates days followed by allo- or auto-HSCT. The remainder of patients were included in 
others clinical trials (Mylotarg, NTC0104104; Flugaza (NCT02319135); Panobidara, NCT00840346). 
Clinical data were collected in the following Spanish AML epidemiological registries: NCT01700413, 
NCT02006004, NCT00464217, NCT02607059, NCT01041040 and NCT01296178. 
 
 





Risk of Death Risk of Relapse 
 
 HR (95%CI) p value HR (95%CI) p value 
Sex (female vs male) 1.20 (0.50–2.83) 0.682 0.94 (0.37–2.44) 0.906 
Age per year 1.04 (1.00–1.07) 0.013 * 1.03 (0.99–1.06) 0.069 
Blasts at dx (%) 1.00 (0.99–1.02) 0.667 1.01 (0.99–1.03) 0.532 
Leukocytes at dx (×109/l) 1.01 (0.99–1.01) 0.418 1.00 (0.99–1.01) 0.508 
Favorable vs adverse (ELN risk) 0.67 (0.08–5.43) 0.714 0.75 (0.09–6.00) 0.786 
Interm. vs adverse (ELN risk) 1.03 (0.13–7.86) 0.976 1.02 (0.13–7.82) 0.988 
Mutated FLT3-ITD 3.45 (1.40-8.52) 0.007 * 2.37 (0.86–6.51) 0.095 
Allo-HSCT vs intensive qt 1.35 (0.40–4.57) 0.634 1.78 (0.41–7.78) 0.44 
Allo-HSCT vs auto-HSCT 0.29 (0.05–1.74) 0.176 0.64 (0.11–3.77) 0.629 
MRD+ by MFC 2.10 (0.67–6.62) 0.203 2.40 (0.77–7.46) 0.130 
MRD+ by qPCR 2.51 (0.56–11.2) 0.228 5.01 (0.64–38.8) 0.123 





 Risk of Death Risk of Relapse 
 HR (95%CI) p value HR (95%CI) p value 
Age per year 1.05  (1.02–1.09) 0.004 * 1.03  (0.99–1.07) 0.061 
Sex (female vs male) 0.84  (0.33–2.17) 0.720 1.25  (0.44–3.52) 0.671 
Leukocytes at dx (×109/l) 1.01  (0.99–1.03) 0.219 1.07  (0.99–1.02) 0.481 
Favorable vs adverse (ELN risk) 13.75 (0.84–226.1) 0.067 7.09 (0.37–134.15) 0.192 
Interm. vs adverse (ELN risk) 11.22(0.82–154.2) 0.071 5.86  (0.39–86.84) 0.203 
Mutated FLT3-ITD 8.87  (2.54–30.95) 0.001 ** 4.18  (1.11–15.69) 0.034 
MRD+ by NGS 4.54  (1.58–13.03) 0.005 ** 3.76  (1.34–10.54) 0.012 * 
 
 (A) Univariate Cox regression analysis of each prognostic factor influencing the risk of relapse and risk of 
death of AML patients. (B) Multivariate Cox regression analysis evaluating the most relevant factors 
detected in univariate analysis. Abbreviations are explained in Table 1. CI indicates confidence interval; Dx, 
diagnosis; ELN, European Leukaemia Net; HR, hazard ratio; MFC, multiparametric flow cytometry; MRD, 
minimal residual disease; NGS, next-generation sequencing; qt, chemotherapy; *p values are considered 





Figure 1. Workflow of NGS-MRD method 
DNA amplification, library preparation and sequencing experimental workflow. gDNA is amplified by 
qPCR using specific primers. Library preparation is carried out in four steps: end repair, adaptor ligation, 
size selection, and PCR amplification. The library is then sequenced. A custom bioinformatic pipeline 
analyzes the obtained sequences. The results are expressed as a ratio of sequences mutated among wild-type 
sequences. 
 
Figure 2. Calibration curve of MRD in serial dilutions 
Top, 10-fold dilution curve for the assessment of sensitivity of sequencing in (A) InDels, using OCI-AML3 
gDNA with 50% NPM1 type A mutation (R2 = 0.98); and in (B) SNV, using OCI-AML3 gDNA with 50% 
mutated DNMT3A (R2 = 0.98), and gDNA with 50% mutated IDH1 or IDH2 from a commercial standard 
(R2 = 0.91, R2 = 0.98, respectively). Bottom, same 10-fold dilution curves for the assessment of sensitivity of 
dPCR in InDels (C, R2 = 0.98); and in SNV (D, R2 = 0.91 for IDH1 and R2 = 0.98 for IDH2).  
Vertical red bars indicate LOQ according to the sample. Clone frequency is expressed as target 
concentration as mutated copies/μL in wild-type copies/μL. Negative control are included in the calibration 
curve and presented levels below the corresponding values of LOQ. 
 
Figure 3. Analysis of OS and DFS in AML patients stratified according to MRD levels by sequencing 
Analysis of OS for induction data set (A), for consolidation data set (C), and both together (E); and for DFS 
for induction data set (B), for consolidation data set (D), and both together (F). At post–induction check-
point (n=35) the cutoff used was 0.001 for OS and DFS. At post-consolidation check–point (n=28) the cut 
off used was 0.00026 for OS and DFS. At both check-point (all data set) the cut off used was 0.00035 
(n=63) for OS and DFS. Number of censored patients with respect to the stratified groups and the number at 
risk is indicated. *P values are considered significant (< 0.05), ** (< 0.01). 
 




Kaplan-Meier plots of (A) OS and (B) DFS with respect to MFC analysis and (C) OS and (D) DFS with 
respect to qPCR analysis. Number of censored patients with respect to each stratified group and number at 








Supplementary 1. Conditions tested during the set-up of the NGS-based method 
 
We tested a variety of methods to find optimal conditions to detect and quantify mutations at very low allele 
frequency in follow-up gDNA samples. 
 
As a first approach, we used the same conditions as those in the diagnosis protocol, with 10 ng of gDNA, 
selected Ampliseq primers and the Ion AmpliSeq DNA & RNA Library Preparation workflow with an 
expected deep coverage of 500,000 reads. In a second approach, we used a higher DNA concentration (30–
50 ng), higher specificity and quality primers (TIB MOLBIOL, Roche Diagnostics, SL) with a more robust 
polymerase (Platinum® PCR SuperMix High Fidelity), and the “Prepare Amplicon Libraries without 
Fragmentation Using the Ion Plus Fragment Library Kit” (Thermo Fisher Scientific, Inc.) and its workflow, 
testing a wide range of internal conditions. The coverage of sequencing was increased to 1,000,000 reads, 
however, the sensitivity was not increased.  
 
Supplementary 2. Conditions of the optimal NGS-based method 
 
DNA extraction was performed in a Maxwell®16 MDx instrument (Promega Biotech Iberica, SL) and 
quantified on a Qubit®2.0 Fluorometer (Invitrogen™, Thermo Fisher Scientific Inc., WA, USA).  
 
The same primer pairs (Supplementary Table S3) used at diagnosis were used to amplify 0.5–1 μg of gDNA 
of patient samples (3 μg for calibration curve assays) by PCR using Platinum™Taq DNA Polymerase High 
Fidelity (Invitrogen™) with the following conditions: 60 seconds at 94ºC for initial denaturation, followed 
by 35 cycles of 15 seconds at 94°C for denaturation, 30 seconds at 58ºC for annealing and 30 seconds at 
68ºC for extension. The final volume was 100 μL (79.6 μL DNA–H2O, 10 μL 10× High Fidelity PCR 
Buffer, 4 μL 50 nM MgSO4, 2 μL 10 mM dNTP Mix (NZYTech, Lda, Lisbon, Portugal), 0.4 μL DNA 
polymerase (5U/μL), and 2 μL each of 10 μM forward and reverse primers. Libraries were constructed 
using NEBNext® Fast DNA Library Prep Set for Ion Torrent™ (New England Biolabs Inc., Ipswich, MA, 
USA). Specificity and quantification of the final product, both for amplified DNA and amplified libraries, 
was analyzed with the Agilent Bioanalyser 2100 (Agilent Technologies, Palo Alto, CA, USA). 
 
The IDH1 and IDH2 dilution curves allowed us established the LOD of NGS at 10–4, based on mean + 2.5 
SD ratio from alternative 1 and alternative 2 results (Supplementary Table S4). In the same way, based on 
mean + 2.5 SD mutated aligned reads from alternative 1 and alternative 2, a technical cutoff was established 
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at 70 mutated aligned reads with a minimum coverage of 100,000 readings aligned, and a prognosis value of 
this cutoff was validated by survival analyses (Supplementary Figure S3).  
 
Supplementary 3. Digital PCR of NMP1 and IDH1/2 mutations  
 
dPCR for 10-fold dilutions curves of NPM1, IDH1 and IDH2 mutated gDNA was performed with specific 
primers and probes. Allele frequency was calculated as the ratio of mutated copies to wild-type copies/μL. 
dPCR assays were performed using QuantStudio™ 3D Digital PCR System using the FAM™/VIC® 
TaqMan® Assay (Applied Biosystems™, Thermo Fisher, La Jolla CA, USA) to study NPM1 type A 
(c.863_864insTCTG), IDH1 (c.394C/T) and IDH2 (c.515G/A). A final volume of 14.5 μL (7.5 μL of PCR 
Master Mix 2×, 0.75 μ L TaqMan® Assay 20× and 6.75 μL of gDNA at 50 ng/μL) was loaded into a 
QuantStudio™ 3D Digital PCR Chip v2 (Thermo Fisher), and amplified by PCR using the GeneAmp® 9700 
system (Thermo Fisher). PCR was performed with the following conditions: 10 minutes at 96ºC for initial 
denaturation, 39 cycles of 2 minutes at 56–60ºC followed by 30 seconds at 98ºC, and a final 2 minutes step 
at 60ºC. After the PCR, each chip was read individually using the QuantStudio™ 3D Digital PCR 
Instrument (Thermo Fisher Scientific, Inc), which generates a file (.eds) containing the processed image 
data that is then interpreted using QuantStudioTM 3D AnalysisSuite Software (Thermo Fisher Scientific, 
Inc). 
 
Supplementary 4. MRD monitoring of NMP1 by qPCR  
 
Detection and quantification of mutated NPM1 transcripts were performed by allele-specific qPCR 
according to the procedure described by Gorello,(1) using RNA as starting sample. The protocol to detect 
NPM1 by RT-PCR was performed in a final volume of 10 μl: 1.5 μL of H2O + 0.5 μL of cProbe-LNA 4 μM 
(5´- 6FAM-ACCAAGAGGCT+A+T+TC+A+A– –BBQ -3´, Isogen Life Science) + 0.5 μL cNPM-F (10 
μM, Isogen Life Science), 5´-GAAGAATTGCTTCCGGATGACT-3´+ 0.5 μL cNPM–mutA-R (10 μM, 
Isogen Life Science), 5´-CTTCCTCCACTGCCAGACAGA-3´+ 5 μL of Taq Man Fast Advanced Master 
Mix (Applied Biosystems) + 2 μL of cDNA. Amplification conditions were: 2 min at 50ºC for enzyme 
activation, 20 seconds at 95ºC for initial enzyme inactivation and AmpliTaq polymerase activation, 
followed by 40 cycles of 60 seconds at 95ºC for denaturation plus 20 seconds at 60ºC for annealing. We 
used the ABI PRISM 7900 Sequence Detection System (Applied Biosystems) for sample amplification and 
analysis. 
 
For normalization of the expression of mutated NPM1, GUS-β expression was used as a control. MRD 
positive status was considered as the presence of NPM1 copies > 0.00001 after therapy.(2) 
 3 
Supplementary 5. MRD monitoring by MFC 
 
After erythrocyte lysis, follow-up bone marrow samples were analyzed using a panel of monoclonal 
antibodies for the detection of the same immunophenotypic alterations described at diagnosis.(3) In our 
study, 10/75 (13%) samples evaluated by MCF were determined with MCF of 8 colours and the remaining 
65/75 (87%) were determined with MCF of 4 colours. MRD positive status by flow cytometry was 
considered as the presence of AML cells greater than 0.001 at post-therapy.(2)  
 
Supplementary 6. Statistical analyses  
 
Contingency tables were used to analyse associations between categorical variables using Fisher´s test or 
Chi-square test for statistical significance. Student´s t-test was used to compare averages of continuous 
variables between groups. The concordance between sequencing, MFC and qPCR was analysed in log space 
using the Spearman correlation test. ROC (receiver operating characteristic) curves were employed to 
establish the cutoff value to predict survival by the NGS method, by MFC or by qPCR; however, for MFC 
and qPCR, the sensitivity and specificity achieved were comparable or less than those using the standard 
thresholds for MRD detections in AML and finally we used these (data not shown). For survival analysis, 
the endpoints examined were disease-free survival (DFS) and overall survival (OS), from the starting point 
of the treatment. In the cases that several samples from the same patient were evaluated, the one in which 
the lowest MRD levels were detected was selected for survival analysis. Survival curves were calculated 
according to the Kaplan-Meier method, and the log-rank test was used for estimation of survival and 
differences between groups. Univariate and multivariate analysis were performed using the Cox regression 
model; the most relevant variables for univariate analysis were: sex, age, blasts at diagnosis, leukocytes at 
diagnosis, cytogenetic risk (ELN recommendation; groups: favorable, intermediate and adverse), mutated 
FLT3-ITD, hematopoietic stem cell transplantation (HSCT) (groups: allo-HSCT, auto-HSCT and therapy), 
and MRD status by each technique (MFC, qPCR, NGS). Variables included in the multivariate analysis 
were chosen based on the results obtained in the univariate analysis and those with greater prognostic 
relevance in AML: sex, age, leukocytes at diagnosis, cytogenetic risk, mutated FLT3-ITD and MRD status 
by NGS.  
Statistical analysis was performed using the R statistical software platform. All p values were two-sided, 
with statistical significance defined as a p–value of 0.05 or less. 
 
Supplementary Table S1. Samples and patients evaluated.  
 
Follow-up samples included in the study and their correlation patient, as well as evaluation time. In those 
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patients where a single sample was studied the patient is noted with the letter M. If several samples were 
studied per patient, these are listed numerically (M1, M2, etc.), and the sample selected for the analysis of 
survival is indicated. The levels of MRD in P3, P9, P38 and P62 patients were evaluated by studying both 
NPM1 and IDH1. The sample selected for survival analysis is indicated. Two patients were removed from 
the study because of a missed follow-up. 
 
Supplementary Table S2. Genes included in the NGS panel  
 
Genes sequenced by NGS grouped by biological function, the chromosome where it is located, genomic 
coordinates (start–end) of region sequenced, the number of amplicons that the gene covers, the region of the 
gene that encompasses all the amplicons expressed as a percentage, and the number of exons.  
 
Supplementary Table S3. Sequences of primers for MRD assay 
 
Specific primer sequences (TIB MOLBIOL, Roche Diagnostics, SL) taken from the custom AML panel 
used at diagnosis (Ion AmpliSeq™, Thermo Fisher Scientific, Inc) for DNMT3A (used only for 
optimization), IDH1, IDH2, and FLT3; or from the commercial panel (Ion AmpliSeq™ AML Panel) in the 
case of NPM1.  
 
Supplementary Table S4. VAF of dilution curves 
 
Table represents the counts of aligned reads, both of the target sequence, wt sequence and the other two 
possible alternatives (sequences not mutated), the ratio (mutated aligned sequences/wt aligned sequences), 
and the fluctuation of the ratio with respect to the mutated sequence [Δlog(ratio)]; according to IDH1 (A) 
and IDH2 dilution curves (B). The LOD (10–4) was established based on ratio mean + 2.5 SD from 
alternative 1 and alternative 2 results.   
 
Supplementary Figure S1. ROC curves  
 
Plots show the sensitivity or true positive rate (TPR) in the y-axis against 1-specificity or the false positive 
rate (FPR) in the x-axis, at various threshold settings. ROC curves determined the optimal cutoff level that 
maximizes sensitivity and specificity for the cases evaluated at each check-point for both OS and DFS 
studies. For OS the sensitivity and the specificity achieved was 0.69 and 0.77 at post-induction, 0.73 and 
0.91 at post-consolidation, and 0.71 and 0.67 at both together. For DFS the sensitivity and the specificity 
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achieved was 0.77 and 0.60 at post-induction, 0.76 and 0.89 at post-consolidation, and 0.72 and 0.67 at both 
together. The area under the curve (AUC) is annotated. 
 
Supplementary Figure S2. Correlation of levels of MRD measure by NGS and conventional methods  
 
Correlation between NGS vs MFC (left) and correlation between NGS vs qPCR (right) detected by 
Spearman test; cases with available data for these tests were included. A significant positive correlation 
were found in both cases: NGS vs MFC (r=0.41, p=0.003), and NGS vs qPCR (r=0.46, p<0.001). 
 
 
Supplementary Figure S3. Prognostic value of technical cutoff 
 
A, OS curves of patients stratified according to MRD status based on technical cutoff (70 aligned mutated 
reads). The group categorized as MRD negative had greater OS than the group categorized as MRD positive 
(HR: 2.55 (1.00–6.46), p=0.049). B, DFS curves of patients stratified under same criteria, the MRD 
negative group had greater DFS than the group categorized as MRD positive (HR: 3.18 (1.16–8.69), 
p=0.024. Number of censored patients with respect to the stratified groups and the number at risk is 
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P61 NPM1 M M
IDH1 M1 M2 M2
NPM1 M1 M2 –
P63 NPM1 M1 M2 M2
– NPM1 M1 M2 –
– NPM1 M –
 n = 106
n=51 n=55





































Onecha.E et al. 
Supplementary Figure S1.
































































































































Post–consolidation (n=55) All data (n=106)
All data (n=106)



























n = 75r = 0.47 p = 0.005









n = 80r = 0.46 p < 0.0001
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